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Abstract
Metabolite quantitative traits carry great promise for epidemiological studies, and their genetic background has been addressed
using Genome-Wide Association Studies (GWAS). Thus far, the role of less common variants has not been exhaustively studied. Here,
we set out a GWAS for metabolite quantitative traits in serum, followed by exome sequence analysis to zoom in on putative causal
variants in the associated genes. 1H Nuclear Magnetic Resonance (1H-NMR) spectroscopy experiments yielded successful
quantification of 42 unique metabolites in 2,482 individuals from The Erasmus Rucphen Family (ERF) study. Heritability of
metabolites were estimated by SOLAR. GWAS was performed by linear mixed models, using HapMap imputations. Based on
physical vicinity and pathway analyses, candidate genes were screened for coding region variation using exome sequence data.
Heritability estimates for metabolites ranged between 10% and 52%. GWAS replicated three known loci in the metabolome wide
significance: CPS1 with glycine (P-value =1.27610232), PRODH with proline (P-value =1.11610219), SLC16A9 with carnitine level
(P-value =4.81610214) and uncovered a novel association between DMGDH and dimethyl-glycine (P-value =1.65610219) level. In
addition, we found three novel, suggestively significant loci: TNP1 with pyruvate (P-value =1.2661028), KCNJ16 with
3-hydroxybutyrate (P-value =1.6561028) and 2p12 locus with valine (P-value =3.4961028). Exome sequence analysis identified
potentially causal coding and regulatory variants located in the genes CPS1, KCNJ2 and PRODH, and revealed allelic heterogeneity
for CPS1 and PRODH. Combined GWAS and exome analyses of metabolites detected by high-resolution 1H-NMR is a robust
approach to uncover metabolite quantitative trait loci (mQTL), and the likely causative variants in these loci. It is anticipated that
insight in the genetics of intermediate phenotypes will provide additional insight into the genetics of complex traits.
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Introduction
Intermediary metabolites in bodily fluids seem a direct
reflection of our genetic constituency in interaction with the
environment, which includes eating habits, life style and other
external factors. Thus, the use of metabolomic phenotypes in
genetic epidemiological studies may provide specific insight in
pathways underlying complex metabolic diseases, such as type 2
diabetes mellitus (T2D), stroke or cardiovascular disease (CVD)
but also other complex diseases such as rheumatoid arthritis,
migraine and depression [1–3]. The sample sizes in the first
genome-wide association studies (GWAS) of metabolite quanti-
tative traits were in general relatively small compared to GWAS
on traditional phenotypes, yet revealed strong signals for
association of common variants with specific metabolites.
Single-proton Nuclear Magnetic Resonance (1H-NMR) spectros-
copy is a metabolomics technique that requires relatively little
sample preparation, yet has the capacity to reproducibly quantify
dozens to more than 100 metabolite signals per measurement.
Several studies have reported genetic loci that influence the
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metabolites quantified by 1H-NMR in plasma and urine [4-7].
Here, we present the results of 42 plasma metabolites quantified
by 1H-NMR spectroscopy in 2,482 individuals of the family-
based Erasmus Rucphen Family (ERF) study, a Dutch genetic
isolate. We estimated the heritability and the effect of shared
environment (household effect) for these metabolites. The GWA
was followed by high-resolution analysis of coding variants in the
candidate genes that were identified by physical proximity and
pathway analysis. To provide further insight into the pathogenesis
of cardio-metabolic diseases, we also investigated the association
between the NMR metabolites and the classical risk factors for
CVD and T2D.
Results
Heritability estimates and GWAS results
The study was conducted in the ERF population (see S1 Table)
using fasting serum samples. After quality filtering, we resolved 42
metabolites, for which the identity was confirmed by the typical
chemical shifts of the related peaks, their high correlation with
other peaks and spiking of pure compounds in serum (S2 Table).
Heritability estimates of the metabolites were moderate to high
ranging from 10% to 52% whereas estimates for the shared
environmental effect ranged from 0% to 8% (Fig. 1). The highest
heritability is observed for citrate (52%), followed by phenylalanine
(51%), ornithine (47%) and methanol (45%) whereas the lowest
heritability estimate was 10% for 3-hydroxybutyrate. We per-
formed genome-wide association (GWA) analysis for all metabolite
SNP pairs, including 2.5 M SNPs from the HapMap2 reference
panel, see S1 Fig. for the Q-Q plots of the 42 metabolites. In total,
we found eight unique genomic loci that associated with NMR
metabolites below the genome-wide significant P-value threshold
(P-value ,5.061028) as shown in the Manhattan plot (Fig. 2).
Regional plots of the 8 loci are shown in S2 Fig.. Four of these loci
were also significant after correction for the number of metabolites
analyzed (P-value,1.1061029) and three of these were previously
shown to associate with the same metabolites: rs715 located in the
39UTR of the carbamoyl-phosphate synthase 1 (CPS1) gene
associated with glycine level (P-value = 1.27610232) [8],
rs2540641 35 Kb distant from proline dehydrogenase (oxidase) 1
(PRODH) gene (P-value = 1.11610219) associated with proline
levels [9] and rs1171614 in the 5’UTR of SLC16A9 (solute carrier
family 16, member 9) associated with carnitine level (P-value
= 4.81610214) [9–11]. The association between intronic SNP
rs248386 within DMGDH (dimethyl-glycine dehydrogenase) and
dimethyl-glycine level is a novel finding (P-value = 1.65610219).
This locus has also been associated with betaine, which is a closely
related metabolite [8].
Four other suggestively significant loci were uncovered by our
analyses (5.061028.P-value.1.1061029). One of these has
previously been identified in urine: the association between
rs8056893 within the SLC7A9 (solute carrier family 7 member
9) and lysine (P-value = 1.2661028) [12]. Three novel associations
were found (1) rs1922005 located inside the TNP1 (transition
protein 1) gene and pyruvate level (P-value = 1.2661028), (2)
rs9896573 located nearby KCNJ16 (potassium inwardly-rectifying
channel, subfamily J, member 16) and 3-hydroxybutyrate level (P-
value = 1.6561028) (3) rs11687765 located in a non-protein
coding region on chromosome 2 and valine level, (P-value
= 3.4961028). For the 8 top loci, we also investigated the mode of
inheritance. The model supervised analysis in those regions of
interest shows that the recessive genetic model applies successfully
for six of the effect alleles: rs715 (CPS1) on glycine, rs1922005
(TNP1) on pyruvate rs248386 (DMGDH) on dimethyl-glycine,
rs1171614 (SLC16A9) on carnitine, rs8056893 (SLC7A9) on
lysine and rs2540641 (PRODH) on proline. For rs11687765
(intergenic on chromosome 2) affecting valine, the mode of
inheritance seems to be dominant for the effect allele. For
rs9896573 (KCNJ16) affecting 3-hydroxybutyrate, the over-
dominant model resulted in the strongest association among the
models tested.
Fine mapping within the candidate genes. In the same
study population exome sequences of 921 individuals from the
ERF pedigree were analyzed for potentially causal SNPs in
biologically plausible genes which were extracted using an
automated workflow, within the top eight GWAS loci in Table 1.
The outputs of the automated workflow are given in S1 Text. In
addition to coding region variation, a number of intronic variants
that were captured around the intron-exon connections, as well as
nearby 5’UTR and 39UTR variants were captured by sequencing
and those were also included in analysis. This approach revealed
in total seven independent SNPs with potentially causal effects
located inside CPS1, KCNJ2 (potassium inwardly-rectifying
channel, subfamily J, member 2), PRODH and SLC25A1 (solute
carrier family 25 member 1) (Table 2). More precisely, for glycine
we found evidence for two independent effects within the CPS1
gene. First, the missense mutation Thr1412Asn (rs1047891) within
CPS1 is the most likely causal variant tagged by the GWAS SNP
rs715, due to the high LD (R2 = 0.92) and large drop in P-values
after conditioning the SNP-metabolite associations for each other.
Second, we found three intronic variants in strong LD with each
other (R2.0.89) in CPS1 that independently associated with
glycine (lowest P-value = 2.5561025 for rs182548513, Table 2)
when conditioned on the leading GWAS SNP. For 3-hydroxybu-
tyrate, we found that rs173135 located 39UTR of KCNJ2 gene is
most likely the causal SNP (P-value = 1.01610207) influencing the
circulating level of this metabolite. Rs173135 is in strong LD with
the leading GWAS SNP (R2 = 0.72) showed a large drop in P-
value, yet remained significant in the conditional analysis (P-value
= 0.002). For proline, in total, we observed four independent
effects within the PRODH locus including one missense mutation
Thr116Asn (rs5747933, P-value = 1.8261029), two intronic
Author Summary
Human metabolic individuality is under strict control of
genetic and environmental factors. In our study, we aimed
to find the genetic determinants of circulating molecules
in sera of large set of individuals representing the general
population. First, we performed a hypothesis-free genome
wide screen in this population to identify genetic regions
of interest. Our study confirmed four known gene
metabolite connections, but also pointed to four novel
ones. Genome-wide screens enriched for common inter-
genic variants may miss causal genetic variations directly
changing the protein sequence. To investigate this further,
we zoomed into regions of interest and tested whether the
association signals obtained in the first stage were direct,
or whether they represent causal variations, which were
not captured in the initial panel. These subsequent tests
showed that protein coding and regulatory variations are
involved in metabolite levels. For two genomic regions we
also found that genes harbour more than one causal
variant influencing metabolite levels independent of each
other. We also observed strong connection between
markers of cardio-metabolic health and metabolites. Taken
together, our novel loci are of interest for further research
to investigate the causal relation to for instance type 2
diabetes and cardiovascular disease.
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SNPS (rs1076466, P-value = 6.3461024 and rs3213491, P-value
= 7.4861024) and one (semi-)independent SNP rs13058335 (R2
= 0.66 with the leading GWAS SNP), explaining the GWAS
finding with a conditional P-value = 1.2061025. We also found
significant coding variations associated with dimethyl-glycine,
carnitine, pyruvate and lysine however all those signals vanished
after adjustment by the leading GWAS SNP, indicating that these
associations so far are best explained by the leading GWAS hits in
these regions (S3 Table).
eQTL and functional effects. We used the GTEX and
GEUVADIS [13] databases to check if the significantly associated
SNPs affect cis gene expression. We obtained evidence that the
leading GWAS SNP for carnitine (rs1171614) influenced the
expression of SLC16A9 in lymphoblasts (P-value = 8.9161026)
and rs8056893 (associated with lysine) influenced the expression of
ZPF90 in lymphoblasts (P-value = 4.0161026) and SLC7A9 in
thyroid cells (P-value = 0.00008). Rs248386 (associated with
dimethyl-glycine) associated with the expression of BHMT
(betaine—homocysteine S-methyltransferase) in the tibial nerve
(P-value = 0.000066). One of the missense variants; Thr1412Asn
(rs1047891) in CPS1 predicted to be ‘‘tolerated’’ by SIFT and
‘‘benign’’ by Polyphen functional predictions. The other missense
variant Thr116Asn (rs5747933) on PRODH predicted to be
‘‘tolerated’’ by SIFT and ‘‘possibly damaging’’ by Polyphen.
Correlation with classical risk factors. Within the ERF
population, we found that BMI correlated positively with carnitine
(r = 0.136, P-value = 4.40610211), proline (r = 0.123, P-value
= 2.8061029), pyruvate (r = 0.240, P-value = 5.40610232), lysine
(r = 0.132, P-value = 1.45610210), and valine (r = 0.383, P-value
= 2.05610282) (S4-A Table), whereas BMI correlated negatively
with glycine (r =20.178, P-value = 4.19610218). After additional
adjustment for BMI, we observed that pyruvate, lysine and valine
correlated positively with risk factors of T2DM, whereas glycine
correlated negatively with triglycerides and C-reactive protein
(CRP) (S4-B Table). Dimethyl-glycine particularly correlated with
measures of kidney function; uric acid (r = 0.21, P-value
= 2.4261029), glomerular filtration rate (eGFR) (r =20.14, P-
value = 2.53610210), urea (r = 0.18, P-value = 1.2061027), and
creatinine (r = 0.22, P-value = 1.35610222).
We also explored possible relationships between the eight
mQTL and the classical risk factors. Among the metabolites which
associate with BMI, none of the mQTLs were associated with BMI
itself in the ERF population. In addition, the association of the
mQTLs with the metabolites glycine, carnitine, proline, pyruvate,
Fig. 1. Heritability and sibship effects on the NMRmetabolites. Figure shows the magnitude of heritability (H2) and sibship (household) effect
estimates for each metabolic trait included in the ERF population.
doi:10.1371/journal.pgen.1004835.g001
Fig. 2. GWAS results of the NMR metabolites. Figure shows the aggregated Manhattan plot for the 42 metabolites studied. Red line shows the
suggestive genome-wide significance level with a P-value of 561028.Loci harbouring DMGDH, SLC16A9, PRODH and CPS1 are reported as
metabolome wide significance.
doi:10.1371/journal.pgen.1004835.g002
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lysine and valine did not change after adjustment for BMI (S5
Table). Interestingly, only for rs11687765 (valine-QTL) associa-
tion with risk factors reached nominally significant P-values:
specifically glucose (P-value = 0.013), HOMA, insulin resistance
(P-value = 0.049) and gynoid fat mass (P-value = 0.003).
Association of rs11687765 with HOMA-insulin resistance dropped
when adjusted by the valine level itself (P-value = 0.122).
Discussion
In this study, we report on the heritability, GWAS, candidate
genes and fine genetic mapping of 42 metabolites identified and
quantified using 1H-NMR spectroscopy in the Erasmus Rucphen
Family (ERF) study. In 2009, the first GWAS of metabolites
identified by 1H-NMR spectroscopy measured in human plasma
was reported by Chasman et al. [4]. This study focused primarily
on lipoprotein particle size and content, and did not measure other
metabolites such as organic acids and amino acids, yet reported 43
significant metabolite mQTL. This was followed by three reports
on blood and urine samples [5,6] the largest of which by
Kettunnen et al. involving both small metabolites and lipoprotein
particle sizes, reporting 31 novel mQTL [7]. Recently, Rueedi et
al. reported one novel locus using an untargeted approach [12].
Here, we used 1H-NMR J-Resolved 2D spectrometry followed by
spiking experiments, yielding a reliable certain metabolite
identification. Traditional CVD traits in ERF and other cohorts
in general show a heritability ranging from 20% to 30% [14]. In
the present study, we observed a similar distribution of heritability
for NMR detected metabolites, ranging from 10% to 52%. These
heritability estimates seem somewhat lower than those found in
the NMR GWAS by Kettunen et al. [7]. However, in that report a
significant proportion of the reported NMR traits and heritability
estimates concern lipoprotein particle characteristics. Since, in
general, heritability for lipoproteins is high [7], ranging from 30%
to 50%, this could explain the apparent discrepancy with our
reported heritability data.
Using verified metabolites, we replicated three known loci and
uncovered a novel association for dimethyl-glycine in the vicinity
of the biologically plausible genes DMGDH and BHMT. This was
expected since our study had 62 to 100% power to detect genetic
variants with 0.2 to 0.5 effect size with metabolome-wide
significant P-value (1.161029) for a bi-allelic marker with 0.3
MAF (for instance rs715 in CPS1) based on the assumption of
complete LD with the causal genetic variant. For more rare
variants with larger effect size such as rs248386 in DMDGH with
0.15 MAF and 0.4 effect size the power on metabolome wide
significance was 100%. Furthermore, we report suggestive
common genetic variants; first in an intergenic region on
chromosome 2 for valine, second in TNP1 for pyruvate and lastly
in KCNJ16 for 3-hydroxybutyrate levels. Analysis of the coding
sequence in the candidate genes uncovered potentially causal
signals within CPS1, KCNJ2 and PRODH that explain the
GWAS hits, as well as additional independent signals located in
CPS1 and PRODH indicating allelic heterogeneity within these
genes. Among the eight mQTL, rs715 in CPS1 explained the
highest (10%)of the total phenotypic variance in circulating glycine
levels (Table 1).This was higher than the total explained variance
in for glycine level by age and sex. (S6 Table).
The CPS1 locus has been previously found associated with
kidney disease, homocysteine, and several metabolite levels
including glycine. CPS1 mutations are known to cause carba-
moylphosphate synthetase I deficiency, an autosomal recessive
inborn error of metabolism of the urea cycle which causes
hyperammonemia. The disease may also have a delayed onset in
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adulthood and is associated with chronic kidney disease. Gene-
network predictions for this gene included functions such as
triglycerides (TG) and lipoprotein homeostasis. In our study, we
also found association of the same SNP with creatine level and also
observed a significant correlation between creatine and glycine
(r = 0.08, P-value = 1.4661024), glomerular filtration rate (r =2
0.09, P-value = 7.0761025) and TG (r =20.08, P-value
= 1.1561024). We identified Thr1412Asn in CPS1 as a potential
variant that may alter the protein function. The second
independent signal within CPS1 was located intronic
(rs182548513). The neighbouring SNP, rs147937942, (Table 2)
in LD with rs182548513 is located on 59UTR of a CPS1
transcript variant (CPS1-001), and identified as transcription
factor binding site according to the ENCODE database however,
so far we did not find any evidence that the SNP affects expression
which may be tissue specific.
The second locus, PRODH, a gene highly expressed in cerebral
cortex, cerebrum and other brain tissues is known to be involved
in proline metabolism, but also in central nervous system
myelination. The locus was previously shown to associate with
schizophrenia [15] and autism [16]. We show in total 4
independent SNPs that associate with circulating proline level;
including (1) the GWAS hit, (2) one very common SNP (tagged by
rs2008720), (3) a possibly damaging missense mutation with low
frequency (MAF =0.03, Thr167Asn) and (4) another with MAF
=0.05 (rs3213491). It is important to mention that rs2008720
maps to first exon of PRODH (PRODH-001 isoform) resulting
the amino-acid change Pro19Gln, whereas it also maps to the
promoter regulatory region of another PRODH isoform
(PRODH-004). Neither for these variants did we find experimen-
tal evidence from eQTL database.
DMGDH codes for the enzyme dimethyl-glycine dehydrogenase
which is involved in catabolism of choline, catalyzing the oxidative
demethylation of dimethyl-glycine to form sarcosine. The gene is
highly expressed in liver, followed by kidney. Mutations in this
gene cause an inborn error of metabolism characterized by
unusual fish-like body odour. Functional predictions for this gene
by KEGG database include several functions in amino-acid
metabolism and bile acid synthesis. Conditional analysis in this
region showed that the GWAS hit located intronic in DMGDH
(rs248386) is most likely the causal variant. Interestingly we found
this SNP associated with the expression of the neighbouring gene,
BHMT that is also involved in dimethyl-glycine and betaine
metabolism.
SLC16A9 is involved in drug transport, bile salt and organic
anion transport and has been previously shown to be associated
with carnitine, uric acid levels. In the ERF population carnitine
and uric acid are highly correlated (r = 0.25, P -value
= 3.93610213). For this locus, we did not find any potentially
causal coding variants. However, the GWAS hit (rs1171614)
located 59UTR of SLC16A9 influences the expression of
SLC16A9 in both GTEX and GEUVADIS databases, indicating
that the effect on carnitine level is possibly through expression,
rather than the change in protein function.
The metabolite pyruvate is the product of anaerobic glycolysis.
Pyruvate levels correlate with gynoid adipose tissue mass, BMI,
waist hip ratio, TG, glucose, HOMA-IR and leptin in the ERF
population (S4B Table). Genes in the TNP1 locus, particularly
IGFBP5 have been previously associated with visceral adipose
tissue mass in men [17]. Within these genes, we did not find any
causal variants, neither for the GWAS hits were we unable to
uncover downstream eQTL. For 3-hydroxybutyrate, rs173135
located in the 39UTR of KCNJ2 is the most likely causal variant
tagged by the GWAS hit for 3-hydroxybutyrate. The gene is
predominantly expressed in heart muscles but also in brain and the
locus has been previously associated with QT interval and cardiac
repolarization. Currently, it is not known how this gene may be
affecting 3-hydroxybutyrate levels. The association between
SLC7A9 and valine has previously been shown [9]. Within the
candidate genes in this locus, we were not able to detect any causal
variants. However, the leading GWAS SNP is associated with
expression of SLC7A9 and ZPF90. Finally, valine has been
suggestively associated with an intergenic region with no eQTL
association. This region has been previously shown to associate
with bilirubin level, which is a determinant of hepatic health. The
strong correlation between valine and pyruvate levels and the risk
factors of T2DM suggests these loci are candidates for T2DM
research. Using the data from the ERF population, for 7 out of 8
loci, we found no evidence that the mQTL discovered directly or
indirectly influenced the risk factors for common diseases. Our
data indicate that the association between these mQTLs and the
metabolites were independent of disease risk factors. For BMI, our
results support an additive effect of BMI and mQTL, both
influencing the metabolite levels. We did find evidence for an
association between HOMA insulin resistance, valine and
rs11687765. However, this finding asks for replication in
independent larger sized studies.
Altogether, our study provides strong evidence for associations
of metabolic traits with a range of novel and previously detected
genetic loci. These loci are potentially of biomedical and
pharmaceutical interest, and may provide insight into human
metabolic and disease pathways.
Methods
Study cohort
The Erasmus Rucphen Family (ERF) study is a cross-sectional
cohort including 3000 living descendants of 22 couples who had at
least 6 children baptized in the community church around 1850-
1900. The participants are not selected on any disease or other
outcome (S1 Table). Details about the genealogy of the population
have been described elsewhere[18]. The study protocol was
approved by the medical ethics board of the Erasmus MC
Rotterdam, the Netherlands.
1H-NMR JRES measurements
2,640 sera of ERF participants were submitted for 1H-NMR
experiments. All NMR experiments were acquired on a
600 MHz Bruker Avance II spectrometer (Bruker BioSpin,
Karlsruhe, Germany). For this study the 2D J-resolved (JRES)
and CPMG (Carr-Purcell-Meiboom-Gill) methods were used.
Data processing was performed in Topspin and Matlab (R2009a,
The Mathworks Inc., Natick, MA, USA). After eliminating low-
quality spectra after a QC procedure, metabolite intensities were
obtained from the serum CPMG spectra by applying a linear
model. The model was constructed by identifying well-resolved
peaks in the 2D JRES spectrum, and relating the intensity of the
peak representing the metabolite with the intensity profile of the
much more convoluted CPMG spectrum. This way, the higher
resolution of the JRES 2D spectrum is combined with the better
signal-to-noise of the CPMG spectrum. After quality control
peaks in the JRES projection were automatically deconvoluted by
fitting the spectra with mixed Gauss-Lorentz line-shapes using the
Simplex method yielding 256 deconvoluted peaks, 42 metabolites
could be reliably assigned using a combination of chemical shift
interpretation, cross-correlation between peaks and spiking of
pure compounds in a mixed serum sample of them were
annotated to unique metabolites (S2 Table). Further selection
Genetic Variants Influencing NMR Metabolome
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procedure and QC and the list of unique metabolites studied are
given in the supplement.
Heritability analysis
Heritability estimations for all metabolite concentrations were
obtained using SOLAR version 6.6.2 software using a polygenic
model and sex and age as covariates.
Genome-wide association analyses
Data points below or above 4 standard deviations from the
mean were removed and non-missing data points of all variables
were rank transformed using the ‘‘rank’’ function in R, this
function takes the missing values into account. No samples were
detected as outliers. DNA samples were genotyped according to
the manufacturer’s instructions on Illumina Infinium Human-
Hap300v2, HumanHap300v1 or HumanCNV370v1 SNP bead
microarrays. Genotype data were imputed using MACH 1.0
(v1.0.18.c) using the HapMap CEU population (release 22, build
36). As the ERF study included related individuals, testing for
association between lipid and allele dosage was performed using a
mixed model approach as implemented with the ‘mmscore’ option
in the GenABEL software. 1.7–4 (R 2.15.3) [19]. This option
combines the Family Based Score Test for Association (FASTA)
method of Abecasis et al. [20] and kinship matrix estimated from
genotyped SNPs [21]. The total genotype set after imputation
involved dosage information of approximately 2.5 million SNPs.
Among the 2,640 samples, 2,416 were genotyped, following the
exclusion of people on lipid lowering (N=298), in total 2,118
samples were included in the final analysis. To correct for multiple
testing, we used the number of unique metabolites (N= 42) which
yielded a suggestive significance zone that lies between 561028
and 1.261029. Details are described in the S2 Text.
Automated annotation of GWAS results
In order to facilitate the manual process of assigning genes to a
locus, we used an automated workflow developed in-house to
generate reports containing the associated protein, enzyme,
metabolic reaction, pathway, and disease phenotypes of every
gene within a window of 1 MB of the locus. In addition, SNPs
published in the GWAS catalog [22] and eQTLs from the GTEx-
eQTL database. (http://www.ncbi.nlm.nih.gov/gtex/GTEX2)
were given. In detail, the reports created by our workflow were
based on the dbSNP [23], NCBI-Gene (http://www.ncbi.nlm.nih.
gov/gene), GTEx-eQTL, GWAS catalog, ConsensusPathDB [24],
UniProtKB [25], OMIM [26], TCDB [27], ExPASy [28] and
KEGG database [29]. The databases had been downloaded
earlier from the respective ftp servers and have been integrated
offline in Matlab. For the KEGG database the last freely available
version was used (30-6-2011).
Exome sequencing
Coding variant analysis were performed within the 3rd data
freeze (N=1309) from the ERF pedigree which were sequenced
‘‘in-house’’ at the Center for Biomics of the Cell Biology
department of the Erasmus MC, The Netherlands, using the
Agilent version V4 capture kit on an Illumina Hiseq2000
sequencer using the TruSeq Version 3 protocol. The sequence
reads were aligned to the human genome build 19 (hg19) using
BWA and the NARWHAL pipelines [30,31]. After processing,
genetic variants were called using the Unified Genotyper tool from
the GATK. The effects of the called variants on the respective
protein sequences were determined with a custom variant
annotation script. For each sample, at least 4 Gigabases of
sequence was aligned to the genome. All variants in the vicinity of
the genes of interest were selected for further analysis. Variants
with less than 5 observations were removed. Of the 1,309
individuals with exome sequencing data, 921 had eligible NMR
metabolite measurements. Single variant analyses were performed
using and additive model as implemented in the ‘‘mmscore’’
function in GenABEL v.1.7–4, adjusting for relatedness.
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